126 related articles for article (PubMed ID: 308621)
1. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
Anders TF; Cann HM; Ciaranello RD; Barchas JD; Berger PA
Neuropadiatrie; 1978 May; 9(2):157-66. PubMed ID: 308621
[TBL] [Abstract][Full Text] [Related]
2. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report.
Anderson LT; Herrmann L; Dancis J
Neuropadiatrie; 1976 Nov; 7(4):439-42. PubMed ID: 1087383
[TBL] [Abstract][Full Text] [Related]
3. The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
Ciaranello RD; Anders TF; Barchas JD; Berger PA; Cann HM
Child Psychiatry Hum Dev; 1976; 7(2):127-33. PubMed ID: 1088261
[TBL] [Abstract][Full Text] [Related]
4. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.
Jankovic J; Caskey TC; Stout JT; Butler IJ
Ann Neurol; 1988 May; 23(5):466-9. PubMed ID: 2455472
[TBL] [Abstract][Full Text] [Related]
5. Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch-Nyhan syndrome.
Frith CD; Johnston EC; Joseph MH; Powell RJ; Watts RW
J Neurol Neurosurg Psychiatry; 1976 Jul; 39(7):656-62. PubMed ID: 792398
[TBL] [Abstract][Full Text] [Related]
6. Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome.
Castells S; Chakrabarti C; Winsberg BG; Hurwic M; Perel JM; Nyhan WL
J Autism Dev Disord; 1979 Mar; 9(1):95-103. PubMed ID: 312282
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
[TBL] [Abstract][Full Text] [Related]
8. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
[No Abstract] [Full Text] [Related]
9. Letter: Self mutilation in Lesch-Nyhan syndrome.
Mizuno TI; Yugari Y
Lancet; 1974 Apr; 1(7860):761. PubMed ID: 4132504
[No Abstract] [Full Text] [Related]
10. Altered excreton of 5-hydroxyindoleacetic acid and glycine in patients with the Lesch-Nyhan disease.
Sweetman L; Borden M; Kulovich S; Kaufman I; Nyhan WL
Adv Exp Med Biol; 1977; 76A():398-404. PubMed ID: 300980
[No Abstract] [Full Text] [Related]
11. Behavior in the Lesch--Nyhan syndrome.
Nyhan WL
J Autism Child Schizophr; 1976 Sep; 6(3):235-52. PubMed ID: 1086851
[TBL] [Abstract][Full Text] [Related]
12. The Lesch-Nyhan syndrome.
Nyhan WL
Dev Med Child Neurol; 1978 Jun; 20(3):376-80. PubMed ID: 307504
[No Abstract] [Full Text] [Related]
13. Serotonergic approaches to the modification of behavior in the Lesch-Nyhan Syndrome.
Nyhan WL; Johnson HG; Kaufman IA; Jones KL
Appl Res Ment Retard; 1980; 1(1-2):25-40. PubMed ID: 6978104
[No Abstract] [Full Text] [Related]
14. Post-hypoxic intention myoclonus treated with 5-hydroxy-tryptophan and an extracerebral decarboxylase inhibitor.
Magnussen I; Dupont E; Engbaek F; de Fine Olivarius B
Acta Neurol Scand; 1978 Apr; 57(4):289-94. PubMed ID: 307327
[TBL] [Abstract][Full Text] [Related]
15. Carbamazepine trial for Lesch-Nyhan self-mutilation.
Roach ES; Delgado M; Anderson L; Iannaccone ST; Burns DK
J Child Neurol; 1996 Nov; 11(6):476-8. PubMed ID: 9120227
[TBL] [Abstract][Full Text] [Related]
16. [The effect of risperidone on the self-mutilation of Lesch-Nyhan syndrome].
Saito Y; Yamashita S; Kaneko K; Kimura S; Osawa M
No To Hattatsu; 2001 May; 33(3):281-2. PubMed ID: 11391974
[No Abstract] [Full Text] [Related]
17. Reduction of self-mutilating behavior and improved oromotor function in a patient with Lesch-Nyhan syndrome following botulinum toxin injection: A case report.
Gilbert C; Sauer M; Cheng J
J Pediatr Rehabil Med; 2021; 14(1):133-136. PubMed ID: 33720862
[TBL] [Abstract][Full Text] [Related]
18. Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient.
Allen SM; Rice SN
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jul; 20(5):793-800. PubMed ID: 8870064
[TBL] [Abstract][Full Text] [Related]
19. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
Van Woert MH; Sethy VH
Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
[TBL] [Abstract][Full Text] [Related]
20. Palatal myoclonus treated with 5-hydroxytryptophan and a decarboxylase-inhibitor.
Magnussen I; Dupont E; Prange-Hansen A; de Fine Olivarius B
Acta Neurol Scand; 1977 Mar; 55(3):251-53. PubMed ID: 300537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
